TEOA Inhibits Proliferation and Induces DNA Damage of Diffuse Large B-Cell Lymphoma Cells Through Activation of the ROS-Dependent p38 MAPK Signaling Pathway

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma, accounting for approximately 30% to 40% of non-Hodgkin’s lymphomas (NHL). The administration of rituximab significantly improved the outcomes of DLBCL; however, the unavoidable development of resistance limits the long-ter...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xingxing, Wang, Xin, Wang, Xu, Zhou, Yi, Li, Yanchun, Wang, Aiwei, Wang, Tongtong, An, Yihan, Sun, Weidong, Du, Jing, Tong, Xiangmin, Wang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500465/
https://www.ncbi.nlm.nih.gov/pubmed/33013393
http://dx.doi.org/10.3389/fphar.2020.554736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500465/
https://www.ncbi.nlm.nih.gov/pubmed/33013393
http://dx.doi.org/10.3389/fphar.2020.554736

Ejemplares similares